Behavioural, Virological And Immunological Factors Influencing Hepatitis C Virus Infection In Injecting Drug Users
Funder
National Health and Medical Research Council
Funding Amount
$963,437.00
Summary
The hepatitis C virus (HCV) is a major public health problem affecting over 170 million people worldwide. In Australia an estimated 157,000 people have HCV and are at risk of serious disease, and 16,000 new infections occur each year. Treating HCV-related disease is expensive, and this healthcare burden is projected to grow significantly in coming years. Almost all new HCV infections in Australia occur among injecting drug users (IDUs), and despite our world-leading prevention programs, the viru ....The hepatitis C virus (HCV) is a major public health problem affecting over 170 million people worldwide. In Australia an estimated 157,000 people have HCV and are at risk of serious disease, and 16,000 new infections occur each year. Treating HCV-related disease is expensive, and this healthcare burden is projected to grow significantly in coming years. Almost all new HCV infections in Australia occur among injecting drug users (IDUs), and despite our world-leading prevention programs, the virus is spreading. Consensus is emerging that the best hope for control of HCV and related disease lies in a vaccine; our research will lay much of the groundwork for its development. The applicants' research to date shows that IDUs are being infected with HCV more frequently than previously assumed, that many carry multiple strains, and that dominant strains vary rapidly in individuals over time. These results reinforce the view that our prevention methods will not reduce infection rates and that current anti-viral treatments are not the solution. Nevertheless, we also found that some IDUs remain free of HCV infection despite risky behaviour with infected associates; intensive study of the immune functioning of these persistently non-infected individuals holds promise for vaccine development. In our proposed research, a collaboration of leading Australian epidemiologists, virologists and immunologists, we will recruit 210 young IDUs and follow them regularly for two years. Recruits will describe their social networks and nominate IDUs with whom they inject, provide blood samples and be interviewed about their behaviour at 3-month intervals. Individuals with recent and resolved HCV infection, change of dominant strain and lack of infection despite risky behaviour will be identified and their blood analysed for genetic factors that may be linked to immune protection. The outcomes will be crucial to the development and trialling of a vaccine against HCV.Read moreRead less
Risk Factors For Long-term Chronic Disease Events In HIV-positive Persons: The D:A:D Cohort Study
Funder
National Health and Medical Research Council
Funding Amount
$925,659.00
Summary
The D:A:D Study is a large, international study assessing risk factors for chronic disease events in HIV-positive patients. We know these events, such as heart attacks and cancers, increase with age. And we also know that these events are more common in HIV-positive people. Over the next five years, D:A:D will assess risk factors for chronic disease events in HIV-positive people as they age, and help optimise patient monitoring and management.
Enterovirus, Vitamin D Status And Inflammation At The Clinical Onset Of Type 1 Diabetes In Childhood
Funder
National Health and Medical Research Council
Funding Amount
$410,542.00
Summary
Type 1 diabetes is a serious disease that is increasing in incidence among Australian children. This project will build on an exsisting study to provide new information on the role of enteroviral infection, vitamin D status and the associated inflammatory changes in blood at the onset of disease.
HIV Pre-exposure Prophylaxis In Men Who Have Sex With Men: Investigating Impacts On HIV Incidence And Novel Methods Of Engagement
Funder
National Health and Medical Research Council
Funding Amount
$318,768.00
Summary
HIV infections are increasing in gay men and other men who have sex with men (MSM) in Australia and Indonesia. A promising new HIV prevention strategy is HIV pre-exposure prophylaxis (PrEP), which involves HIV-negative individuals taking one pill containing HIV treatments per day to prevent infection. PrEP is highly effective when taken correctly. Access to PrEP is currently very limited. Studies to investigate the best ways to implement PrEP services are required in Australia and Indonesia.
HIV Treatment As Prevention: A Longitudinal Assessment Of Population Effectiveness
Funder
National Health and Medical Research Council
Funding Amount
$783,160.00
Summary
This project is a large-scale evaluation of an HIV strategy known as ‘treatment as prevention’ (TasP). Through routine and repeat HIV testing for gay men and early treatment initiation following diagnosis, TasP aims to reduce HIV community infection rates. Through the establishment of a large cohort of gay men in NSW and Victoria, this study will track HIV testing, treatment and management to assess the real-world efficacy of TasP for reducing HIV infections among this at-risk population.
People With HIV Still Die Young – Preventing Non-AIDS-associated Comorbidity
Funder
National Health and Medical Research Council
Funding Amount
$408,768.00
Summary
There are over 36 million people in the world infected with HIV. While people with HIV can now live an almost normal life through the use of medication, they have a very high risk of heart problems, cancer and other common illnesses. It is important to find ways of reducing the cost of treating these common illnesses and to make sure that people with HIV can live a long, happy life. This project aims to find the best ways to stop people with HIV getting heart trouble or dying from liver cancer.
Evaluating The Burden And Aetiology Of Medical Comorbidities Among People With HIV In Australia: Towards The Optimal Management Of The Ageing HIV Positive Population
Funder
National Health and Medical Research Council
Funding Amount
$105,599.00
Summary
People with HIV are living longer due to better HIV medications. People with HIV also have more medical problems (like heart disease and cancer) than HIV negative persons. Therefore, treating these other medical conditions is becoming a larger part of caring for people with HIV. This research focuses on: 1) Understanding how common these medical conditions are among people with HIV; and 2) Identifying the reasons behind why people with HIV have more medical problems than HIV negative people.
Risk Of Hepatitis C Reinfection Among People With Current Injecting Drug Use Following Successful HCV Treatment
Funder
National Health and Medical Research Council
Funding Amount
$2,245,228.00
Summary
In Australia, hepatitis C (HCV)-related morbidity and mortality are rising. One of the most important recent breakthroughs in clinical medicine is the approval of safe, simple, interferon-free HCV therapies with cure rates >95%. Although people who inject drugs account for the majority of new and existing cases of HCV, reinfection following treatment can occur. The goal of this Project Grant is to examine HCV treatment and reinfection following successful therapy among people who inject drugs ....In Australia, hepatitis C (HCV)-related morbidity and mortality are rising. One of the most important recent breakthroughs in clinical medicine is the approval of safe, simple, interferon-free HCV therapies with cure rates >95%. Although people who inject drugs account for the majority of new and existing cases of HCV, reinfection following treatment can occur. The goal of this Project Grant is to examine HCV treatment and reinfection following successful therapy among people who inject drugs.Read moreRead less